Aspira Pathlab & Diagnostics Ltd - 540788 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Priya PandeyDesignation :- Company Secretary and Compliance Officer Aspira Pathlab & Diagnostics Ltd - 540788 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018, for the quarter ended 30th June, 2022, as received from Link Intime India Pvt. Ltd, the Registrar and Share Transfer Agent (RTA) of the Company. Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
ear Sir/Madam, Please find attached disclosure in Form - C pursuant to Regulation 7(2) read with Regulation 6(2) of the SEBI (Prohibition of Insider Trading) Regulations, 2015. We request you to treat this intimation as compliance with Regulation 7(2)(b) of the SEBI (Prohibition of Insider Trading) Regulations, 2015 and take the same on record. Aspira Pathlab & Diagnostics Ltd - 540788 - Closure of Trading Window
Pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the code of Prohibition of Insider Trading adopted by Company, the trading window for dealing in securities of the company will remain closed from July 01, 2022, till 48 hours after declaration of Financial Results of the Company for the quarter ended June 30, 2022. Aspira Pathlab & Diagnostics Ltd - 540788 - Intimation Of Submission Of Application To BSE Limited For Reclassification Of Shareholder From The ''Promoter'' To The ''''Public'''' Category In Terms Of Regulation 31A Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find enclosed herewith the intimation for application submitted to BSE Limited for Reclassification of Promoter pursuant to request received by the company vide letter dated 12th May, 2022. Aspira Pathlab & Diagnostics Ltd - 540788 - Disclosure Under Regulation 23(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
In terms of Regulation 23 (9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions in the format specified under the SEBI Circular bearing reference no. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021, for the half year ended March 31, 2022. Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement Under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of Notice of Postal Ballot & E-Voting Aspira Pathlab & Diagnostics Ltd - 540788 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
It is hereby informed that approval of members is sought by way of Postal Ballot on the agenda items listed in the Postal Ballot Notice dated May 28, 2022. The Company has completed the dispatch of Postal Ballot Notice in electronic form only as permitted under the MCA & SEBI Circulars. In compliance with Sections 108 and 110 of the Companies Act, 2013 read with the rules framed there under and the MCA & SEBI Circulars, the Company has extended only remote e-voting facility for its members, to enable them to cast their votes electronically instead of submitting the postal ballot form. In this regard, the Company has engaged the services of NSDL for providing e-voting facility. The E-voting period will commence on June 8, 2022 at 09.00 a.m. and would end on July 7, 2022 at 5.00 p.m. The result of postal ballot will be announced on or before July 9, 2022. This is for your information and record. Aspira Pathlab & Diagnostics Ltd - 540788 - Financial Results For The Year Ended March 31, 2022
Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations), this is to inform that Board of Directors of the Company, in their meeting held today i.e. May 28, 2022 has inter-alia considered and approved the Audited Financial Results for the year ended on March 31, 2022. Please find attached: Audited Financial Results for the year ended on March 31, 2022 along with statement of Assets & Liabilities and Cash Flow Statement,Auditors'' Report, and Declaration about unmodified opinion in audit report.